Dr Reddy's Laboratories Limited, the Hyderabad-based pharmaceutical major on 17 September 2013 announced that it received approval for Azacitidine for injection 100 mg/vial by the United States Food and Drug Administration (US FDA). Dr Reddy's Laboratories Limited announced that it was planning to launch this product in the market in a short span of time.
Azacitidine is a bioequivalent generic version of Vidaza (azacitidine for injection) and is a chemotherapy drug. It is primarily used for the treatment of myelodysplastic syndromes (MDS). The Azacitidine for injection 100 mg/vial is available only for single use-vials.
Its generic version brand Vidaza had the US sales of approximately 378.5 million US dollar for the year ending July 2013.
Azacitidine is basically used for the treatment of certain kinds of blood cell disorders as well as bone marrow cancers. It belongs to the class of medications known as demethylation agents. It functions by helping bone marrow in producing normal blood cells as well as by killing the abnormal cells in the bone marrow.